Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2019 Jul;58(7):969-971.
doi: 10.1007/s40262-019-00785-x.

Comment on "Levothyrox® New and Old Formulations: Are They Switchable for Millions of Patients?"

Alain Munafo  1 , Axel Krebs-Brown  2 , Sumedh Gaikwad  2 , Bogumila Urgatz  2 , Claire Castello-Bridoux  3
Affiliations
Comment

Comment on "Levothyrox® New and Old Formulations: Are They Switchable for Millions of Patients?"

Alain Munafo et al. Clin Pharmacokinet. 2019 Jul.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Alain Munafo, Axel Krebs-Brown, Sumedh Gaikwad, Bogumila Urgatz and Claire Castello-Bridoux are employees of Merck KGaA, Darmstadt, Germany, or of one of its affiliates.

Figures

Fig. 1
Fig. 1
Distribution of individual exposure ratio (area under the curve test/area under the curve reference) obtained with unadjusted thyroxine (left panel) and baseline-adjusted thyroxine (right panel) simulated plasma levels. Red and blue vertical dotted lines represent ranges of 0.8–1.25 and 0.9–1.11, respectively. Pharmacokinetic profiles for 10,000 subjects were simulated over the course of 72 h, assuming a bioanalytical error of 10%, no difference in pharmacokinetic profiles under both formulations and the absence of a subject-by-formulation interaction
See this image and copyright information in PMC

Comment in

Comment on

References

    1. Concordet D, Gandia P, Montastruc JL, Bousquet-Mélou A, Lees P, Ferran A, Toutain P-L. Levothyrox® new and old formulations: are they switchable for millions of patients? Clin Pharmacokinet. 2019 doi: 10.1007/s40262-019-00747-3. - DOI - PMC - PubMed
    1. Adkin DA, Davis SS, Sparrow RA, Huckle PD, Phillips AJ, Wilding IR. The effect of different concentrations of mannitol in solution on small intestinal transit: implications for drug absorption. Pharm Res. 1995;12:393–396. doi: 10.1023/A:1016256619309. - DOI - PubMed

LinkOut - more resources